<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1027</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>8496604</PubmedId>
            <Abstract>The specificity of the T cell-immune repertoire at the level of individual antigenic determinants could play a fundamental role in the immunopathogenesis of tuberculous infections. Therefore, we analyzed the immunogenicity, genetic restriction, and epitope core structure of two adjacent, yet distinct, immunodominant T cell determinants from the 19-kDa Ag of Mycobacterium tuberculosis. After immunization with two peptides comprising residues 45 to 64 and 61 to 80, vigorous in vitro proliferative responses to the homologous peptide were elicited in five different strains of C57BL/10 mice (H-2b,k,d,s,f), indicating that both epitopes were recognized in a genetically permissive manner. When immunized with intact 19-kDa protein, lymph node cells from the same mouse strains responded to both peptides, with the exception of H-2b mice, which did not respond to p45-64. Delayed-type hypersensitivity responses in C57BL/10 (H-2b) mice were elicited by p61-80 only, whereas in H-2d mice both peptides were delayed-type hypersensitivity negative, despite eliciting pronounced proliferative responses. Analysis of the proliferative responses of human PBMC in purified protein derivative-positive healthy subjects and tuberculosis patients revealed significant differences in the antigenicity to the two peptides. All purified protein derivative-positive healthy and diseased individuals manifested strong responses to p45-64, indicating HLA permissive recognition. In contrast, pronounced responses to p61-80 were detected only in patients with lymphatic tuberculosis. Epitope core structures, composed of 6 or 7 residues within each peptide, have been mapped with peptides of overlapping sequence. Significantly, for both epitopes, the core sequences recognized by both human and murine T cells were almost identical. We conclude that despite many similarities between murine and human T cell epitope recognition, distinct differences in the responsiveness of the infected host could play a role in pathogenesis. Furthermore, the genetically permissive nature of the identified epitopes is a potentially important attribute for the development of peptide-based diagnostic reagents and vaccines.</Abstract>
            <ArticleYear>1993</ArticleYear>
            <ArticlePages>5041-50</ArticlePages>
            <ArticleTitle>Genetically permissive recognition of adjacent epitopes from the 19-kDa antigen of Mycobacterium tuberculosis by human and murine T cells.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Harris</LastName>
                    <ForeName>D P</ForeName>
                </Author>
                <Author>
                    <LastName>Vordermeier</LastName>
                    <ForeName>H M</ForeName>
                </Author>
                <Author>
                    <LastName>Friscia</LastName>
                    <ForeName>G</ForeName>
                </Author>
                <Author>
                    <LastName>Rom√°n</LastName>
                    <ForeName>E</ForeName>
                </Author>
                <Author>
                    <LastName>Surcel</LastName>
                    <ForeName>H M</ForeName>
                </Author>
                <Author>
                    <LastName>Pasvol</LastName>
                    <ForeName>G</ForeName>
                </Author>
                <Author>
                    <LastName>Moreno</LastName>
                    <ForeName>C</ForeName>
                </Author>
                <Author>
                    <LastName>Ivanyi</LastName>
                    <ForeName>J</ForeName>
                </Author>
            </Authors>
            <Affiliations>MRC Tuberculosis and Related Infections Unit, Royal Postgraduate Medical School, London, United Kingdom.</Affiliations>
            <ArticleChemicalList>Antigens, Bacterial;H-2 Antigens;Immunodominant Epitopes</ArticleChemicalList>
            <ArticleMeshHeadingsList>Adult; Amino Acid Sequence; Animals; Antigens, Bacterial(genetics ); Female; H-2 Antigens(genetics ); Humans; Hypersensitivity, Delayed(immunology; microbiology ); Immunodominant Epitopes(genetics ); Lymphocyte Activation; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Middle Aged; Molecular Sequence Data; Molecular Weight; Mycobacterium tuberculosis(genetics; immunology ); T-Lymphocytes(immunology ); Tuberculosis(immunology )</ArticleMeshHeadingsList>
            <Journal>
                <Volume>150</Volume>
                <Issue>11</Issue>
                <Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
                <Issn>0022-1767</Issn>
                <MedlineTa>J Immunol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>45-64</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>GAASGPKVVIDGKDQNVTGS</LinearSequence>
                        <StartingPosition>45</StartingPosition>
                        <EndingPosition>64</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P0A5J0.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>1773</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 4</LocationOfData>
                <EpitopeId>18526</EpitopeId>
                <ReferenceStartingPosition>45</ReferenceStartingPosition>
                <ReferenceEndingPosition>64</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>Also known as Lipoprotein lpqH precursor.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2 and table II</LocationOfData>
                        <TCellId>1372088</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Exposure with existing immune reactivity without evidence for disease</InVivoProcessType>
                                <DiseaseState>ONTIE:0003423</DiseaseState>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>1773</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Mycobacterium tuberculosis</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Both PPD+ tuberculosis patients and PPD+ healthy donors were assayed with similar results.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>304</MhcAlleleId>
                            <MhcEvidenceCode>T cell assay -Biological process measured</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>45-64</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GAASGPKVVIDGKDQNVTGS</LinearSequence>
                                        <StartingPosition>45</StartingPosition>
                                        <EndingPosition>64</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P0A5J0.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1773</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>69</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>15</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>15</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Significant proliferation of peripheral blood lymphocytes is seen upon incubation with peptide in PPD+ healthy donors, while lymphocytes from PPD- controls are not responsive.  Due to the number of donors responding to the epitope,  this peptide is presumably able to associate with multiple class II HLA molecules. The core epitope recognized by healthy donors spans aas 72-77 (GNVNIA).</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>14695</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000263</OrganismId>
                                <Age>6-10 wk</Age>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>121</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>GAASGPKVVIDGKDQNVTGS</LinearSequence>
                                            <StartingPosition>45</StartingPosition>
                                            <EndingPosition>64</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P0A5J0.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>1773</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>45-64</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>Single dose of 80 micrograms, split into 1 injection at each hind footpad.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Lymph nodes were harvested 8-10 days after immunization.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>121</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>45-64</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GAASGPKVVIDGKDQNVTGS</LinearSequence>
                                        <StartingPosition>45</StartingPosition>
                                        <EndingPosition>64</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P0A5J0.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1773</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>69</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Significant proliferation of peptide immunized lymph node cells is seen upon incubation with peptide. The core epitope recognized by this haplotype is deduced to span aas 54-61 (IDGKDQNV). The 20-mer was shown to induce proliferation in any haplotype (b, k, d, s, f) assayed, implying promiscuous presentation.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>14687</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000051</OrganismId>
                                <Age>6-10 wk</Age>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>170</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>GAASGPKVVIDGKDQNVTGS</LinearSequence>
                                            <StartingPosition>45</StartingPosition>
                                            <EndingPosition>64</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P0A5J0.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>1773</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>45-64</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>Single dose of 80 micrograms, split into 1 injection at each hind footpad.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Lymph nodes were harvested 8-10 days after immunization.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>170</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>45-64</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GAASGPKVVIDGKDQNVTGS</LinearSequence>
                                        <StartingPosition>45</StartingPosition>
                                        <EndingPosition>64</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P0A5J0.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1773</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>69</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Significant proliferation of peptide immunized lymph node cells is seen upon incubation with peptide.  It was also shown to induce proliferation in other haplotypes (k, b, s, f), implying promiscuous presentation. Similar results are seen with BALB/c (also H-2d haplotype) mice.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>14684</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000047</OrganismId>
                                <Age>6-10 wk</Age>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>167</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P0A5J0.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>1773</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>19 kDa lipoprotein antigen</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>Single dose of 80 micrograms, split into 1 injection at each hind footpad.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Lymph nodes were harvested 8-10 days after immunization.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>168</MhcAlleleId>
                            <MhcEvidenceCode>T cell assay -Biological process measured</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>45-64</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GAASGPKVVIDGKDQNVTGS</LinearSequence>
                                        <StartingPosition>45</StartingPosition>
                                        <EndingPosition>64</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P0A5J0.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1773</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>69</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Significant proliferation is not seen upon incubation with peptide of lymph node cells from source protein immunized animals.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2 and table II</LocationOfData>
                        <TCellId>14704</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:399</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>1773</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Mycobacterium tuberculosis</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Both PPD+ tuberculosis patients and PPD+ healthy donors were assayed with similar results.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>304</MhcAlleleId>
                            <MhcEvidenceCode>T cell assay -Biological process measured</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>45-64</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GAASGPKVVIDGKDQNVTGS</LinearSequence>
                                        <StartingPosition>45</StartingPosition>
                                        <EndingPosition>64</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P0A5J0.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1773</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>69</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>15</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>15</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Significant proliferation of peripheral blood lymphocytes is seen upon incubation with peptide in patients with tuberculosis (pulmonary or lymphatic), while lymphocytes from PPD- controls are not responsive. Due to the number of donors responding to the epitope,  this peptide is presumably able to associate with multiple class II HLA molecules. The core epitope recognized by healthy donors spans aas 72-77 (GNVNIA).</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>14683</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000047</OrganismId>
                                <Age>6-10 wk</Age>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>168</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>GAASGPKVVIDGKDQNVTGS</LinearSequence>
                                            <StartingPosition>45</StartingPosition>
                                            <EndingPosition>64</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P0A5J0.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>1773</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>45-64</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>Single dose of 80 micrograms, split into 1 injection at each hind footpad.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Lymph nodes were harvested 8-10 days after immunization.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>168</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>45-64</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GAASGPKVVIDGKDQNVTGS</LinearSequence>
                                        <StartingPosition>45</StartingPosition>
                                        <EndingPosition>64</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P0A5J0.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1773</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>69</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Significant proliferation of peptide immunized lymph node cells is seen upon incubation with peptide. It was also shown to induce proliferation in other haplotypes (k, d, s, f), implying promiscuous presentation.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>14688</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000051</OrganismId>
                                <Age>6-10 wk</Age>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>170</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P0A5J0.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>1773</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>19 kDa lipoprotein antigen</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>Single dose of 80 micrograms, split into 1 injection at each hind footpad.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Lymph nodes were harvested 8-10 days after immunization.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>170</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>45-64</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GAASGPKVVIDGKDQNVTGS</LinearSequence>
                                        <StartingPosition>45</StartingPosition>
                                        <EndingPosition>64</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P0A5J0.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1773</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>69</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Significant proliferation is seen upon incubation with peptide of lymph node cells from source protein immunized animals. It was also shown to induce proliferation in congenic animals of k, s, and f haplotypes, but not in those of b haplotype, implying promiscuous presentation. Similar results are seen with BALB/c (also H-2d haplotype) mice.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>14699</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000263</OrganismId>
                                <Age>6-10 wk</Age>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>121</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P0A5J0.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>1773</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>19 kDa lipoprotein antigen</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>Single dose of 80 micrograms, split into 1 injection at each hind footpad.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Lymph nodes were harvested 8-10 days after immunization.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>121</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>45-64</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GAASGPKVVIDGKDQNVTGS</LinearSequence>
                                        <StartingPosition>45</StartingPosition>
                                        <EndingPosition>64</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P0A5J0.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1773</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>69</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Significant proliferation is seen upon incubation with peptide in lymph node cells from source protein immunized animals.  It was also shown to induce proliferation in congenic animals of d, s, and f haplotypes , but not in those of b haplotype, implying promiscuous presentation.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>61-80</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>VTGSVVCTTAAGNVNIAIGG</LinearSequence>
                        <StartingPosition>61</StartingPosition>
                        <EndingPosition>80</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P0A5J0.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>1773</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 4</LocationOfData>
                <EpitopeId>71346</EpitopeId>
                <ReferenceStartingPosition>61</ReferenceStartingPosition>
                <ReferenceEndingPosition>80</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>Also known as Lipoprotein lpqH precursor.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>14730</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000051</OrganismId>
                                <Age>6-10 wk</Age>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>170</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>VTGSVVCTTAAGNVNIAIGG</LinearSequence>
                                            <StartingPosition>61</StartingPosition>
                                            <EndingPosition>80</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P0A5J0.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>1773</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>61-80</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>Single dose of 80 micrograms, split into 1 injection at each hind footpad.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Lymph nodes were harvested 8-10 days after immunization.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>170</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>61-80</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VTGSVVCTTAAGNVNIAIGG</LinearSequence>
                                        <StartingPosition>61</StartingPosition>
                                        <EndingPosition>80</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P0A5J0.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1773</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>69</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Significant proliferation of peptide immunized lymph node cells is seen upon incubation with peptide.  It was also shown to induce proliferation in other haplotypes (k, b, s, f), implying promiscuous presentation. Similar results are seen with BALB/c (also H-2d haplotype) mice.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2 and table II</LocationOfData>
                        <TCellId>14739</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:399</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>1773</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Mycobacterium tuberculosis</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Both PPD+ tuberculosis patients and PPD+ healthy donors were assayed with similar results.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>304</MhcAlleleId>
                            <MhcEvidenceCode>T cell assay -Biological process measured</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>61-80</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VTGSVVCTTAAGNVNIAIGG</LinearSequence>
                                        <StartingPosition>61</StartingPosition>
                                        <EndingPosition>80</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P0A5J0.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1773</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>69</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>25</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>17</NumberOfSubjectsResponded>
                            <ResponseFrequency>68</ResponseFrequency>
                            <AssayComments>Significant proliferation of peripheral blood lymphocytes is seen upon incubation with peptide in patients with tuberculosis (pulmonary or lymphatc), while lymphocytes from PPD- controls are not responsive. Due to the number of donors responding to the epitope,  this peptide is presumably able to associate with multiple class II HLA molecules. This was confirmed by the recognition of the core epitope (54-60 IDGKDQN) in 4 healthy donors of diverse HLA haplotypes.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>14728</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000047</OrganismId>
                                <Age>6-10 wk</Age>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>168</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>VTGSVVCTTAAGNVNIAIGG</LinearSequence>
                                            <StartingPosition>61</StartingPosition>
                                            <EndingPosition>80</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P0A5J0.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>1773</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>61-80</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>Single dose of 80 micrograms, split into 1 injection at each hind footpad.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Lymph nodes were harvested 8-10 days after immunization.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>168</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>61-80</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VTGSVVCTTAAGNVNIAIGG</LinearSequence>
                                        <StartingPosition>61</StartingPosition>
                                        <EndingPosition>80</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P0A5J0.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1773</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>69</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Significant proliferation of peptide immunized lymph node cells is seen upon incubation with peptide.  It was also shown to induce proliferation in other haplotypes (k, d, s, f), implying promiscuous presentation.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>14729</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000047</OrganismId>
                                <Age>6-10 wk</Age>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>167</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P0A5J0.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>1773</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>19 kDa lipoprotein antigen</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>Single dose of 80 micrograms, split into 1 injection at each hind footpad.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Lymph nodes were harvested 8-10 days after immunization.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>168</MhcAlleleId>
                            <MhcEvidenceCode>T cell assay -Biological process measured</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>61-80</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VTGSVVCTTAAGNVNIAIGG</LinearSequence>
                                        <StartingPosition>61</StartingPosition>
                                        <EndingPosition>80</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P0A5J0.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1773</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>69</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Significant proliferation is seen upon incubation with peptide of lymph node cells from source protein immunized animals.  It was also shown to induce proliferation in other haplotypes (k, d, s, f), implying promiscuous presentation.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>14731</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000051</OrganismId>
                                <Age>6-10 wk</Age>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>170</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P0A5J0.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>1773</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>19 kDa lipoprotein antigen</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>Single dose of 80 micrograms, split into 1 injection at each hind footpad.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Lymph nodes were harvested 8-10 days after immunization.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>170</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>61-80</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VTGSVVCTTAAGNVNIAIGG</LinearSequence>
                                        <StartingPosition>61</StartingPosition>
                                        <EndingPosition>80</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P0A5J0.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1773</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>69</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Significant proliferation is seen upon incubation with peptide of lymph node cells from source protein immunized animals. It was also shown to induce proliferation in other haplotypes (k, b, s, f), implying promiscuous presentation. Similar results are seen with BALB/c (also H-2d haplotype) mice.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2 and table II</LocationOfData>
                        <TCellId>1372094</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Exposure with existing immune reactivity without evidence for disease</InVivoProcessType>
                                <DiseaseState>ONTIE:0003423</DiseaseState>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>1773</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Mycobacterium tuberculosis</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Both PPD+ tuberculosis patients and PPD+ healthy donors were assayed with similar results.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>304</MhcAlleleId>
                            <MhcEvidenceCode>T cell assay -Biological process measured</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>61-80</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VTGSVVCTTAAGNVNIAIGG</LinearSequence>
                                        <StartingPosition>61</StartingPosition>
                                        <EndingPosition>80</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P0A5J0.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1773</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>69</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>20</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>10</NumberOfSubjectsResponded>
                            <ResponseFrequency>50</ResponseFrequency>
                            <AssayComments>Significant proliferation of peripheral blood lymphocytes is seen upon incubation with peptide in PPD+ healthy donors, while lymphocytes from PPD- controls are not responsive. Due to the number of donors responding to the epitope,  this peptide is presumably able to associate with multiple class II HLA molecules. This was confirmed by the recognition of the core epitope (54-60 IDGKDQN) in 4 healthy donors of diverse HLA haplotypes.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>14737</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000263</OrganismId>
                                <Age>6-10 wk</Age>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>121</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P0A5J0.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>1773</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>19 kDa lipoprotein antigen</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>Single dose of 80 micrograms, split into 1 injection at each hind footpad.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Lymph nodes were harvested 8-10 days after immunization.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>121</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>61-80</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VTGSVVCTTAAGNVNIAIGG</LinearSequence>
                                        <StartingPosition>61</StartingPosition>
                                        <EndingPosition>80</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P0A5J0.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1773</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>69</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Significant proliferation is seen upon incubation with peptide of lymph node cells from source protein immunized animals. It was also shown to induce proliferation in other haplotypes (b, d, s, f), implying promiscuous presentation.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>14738</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000263</OrganismId>
                                <Age>6-10 wk</Age>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>121</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>VTGSVVCTTAAGNVNIAIGG</LinearSequence>
                                            <StartingPosition>61</StartingPosition>
                                            <EndingPosition>80</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P0A5J0.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>1773</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>61-80</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>Single dose of 80 micrograms, split into 1 injection at each hind footpad.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Lymph nodes were harvested 8-10 days after immunization.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>121</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>61-80</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VTGSVVCTTAAGNVNIAIGG</LinearSequence>
                                        <StartingPosition>61</StartingPosition>
                                        <EndingPosition>80</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P0A5J0.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1773</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>69</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Significant proliferation of peptide immunized lymph node cells is seen upon incubation with peptide. The core epitope recognized by this haplotype is deduced to span aas 71-78 (AGNVNIAI). The 20-mer was shown to induce proliferation in any haplotype (b, k, d, s, f) assayed, implying promiscuous presentation.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

